central retinal artery perfusion following 0.1 ml intravitreal injection of bevacizumab
نویسندگان
چکیده
purpose: to study the pattern of perfusion of central retinal artery (cra) after 0.1 ml intravitreal injection of bevacizumab to verify the need for any maneuver to decrease the intraocular pressure (iop) including anterior chamber paracentesis (acp) methods: this is a prospective, interventional, noncomparative case series. patients receiving intravitreal injection of bevacizumab for choroidal neovascularization (cnv) secondary to age-related macular degeneration, diabetic macular edema and retinal veno-occlusive diseases were included in the study. each eye received 0.1 ml intravitreal injection of bevacizumab and the status of perfusion of cra and its pulsation was monitored by indirect ophthalmoscopy until cessation of visible pulsation. main outcome measures were patency of cra, its pulsation and time from injection to cessation of pulsation. results: seventy seven eyes of 70 patients were studied. at first ophthalmoscopy 30 seconds after injection, cra was open in all cases with or without pulsation. cra occlusion was not observed in any case. in 20 eyes (26%) cra was patent without pulsation. in 57 eyes (74%) cra pulsation was detected and this visible pulsation of cra stopped within an average time of 167±99 seconds (range: 30-480 seconds). from 17 eyes which had significant vitreous reflux, only 6 eyes had cra pulsation which stopped in a mean time of 80±36 seconds. there was a significant difference between pulsation duration in patients with and without vitreous reflux (mann-whitney u test, p=0.005). absence of postinjection vitreous reflux was a risk factor for cra pulsation after intravitreal injection of 0.1 ml of bevacizumab (relative risk: 2.41, 95% ci: 1.25-4.62). conclusion: considering the absence of cra closure and the short time needed for the cessation of pulsation after intravitreal injection of 0.1 ml bevacizumab, no treatment including acp is warranted before or after such injections in nonglaucomatous eyes. indirect ophthalmoscopy is a noninvasive useful maneuver to ascertain patency of cra after intravitreal injections. iranian journal of ophthalmology 200921(2):13-18 © 2009 by the iranian society of ophthalmology
منابع مشابه
Intravitreal bevacizumab for neovascular glaucoma following central retinal artery occlusion.
PURPOSE To report a case of neovascular glaucoma due to central retinal artery occlusion treated with a single intravitreal injection of bevacizumab. METHODS A 68-year-old patient with a 10-week history of central retinal artery occlusion presented with neovascularization of the iris and the angle and intraocular pressure of 30 mm Hg. The patient received a single injection of 1.25 mg bevaciz...
متن کاملRetinal Angiomatous Proliferation and Intravitreal Bevacizumab Injection
PURPOSE To evaluate the short-term efficacy and safety of intravitreal bevacizumab injection (IVBI) in patients with retinal angiomatous proliferation (RAP). METHODS Seven eyes of 5 patients with RAP were included in this study. All of the eyes evidenced stage 2 RAP lesions, except for one eye with a stage 3 lesion. IVBI (1.25 mg/0.05 cc) were conducted at 4 or 6-week intervals. Complete ocul...
متن کاملMassive Exudative Retinal Detachment Following Photodynamic Therapy and Intravitreal Bevacizumab Injection in Retinal Capillary Hemangioma
ment was recommended, but the patient initially refused. As the clinical findings did not change during follow-up, surgery was performed in August 2014. Restriction of the inferior rectus muscle of the left eye was confirmed through the forced duction test. During surgery, conjunctival scarring over the inferior rectus muscle was noted, in addition to a linear scar along the medial border of th...
متن کاملIntravitreal Injection of Bevacizumab (Avastin) to Treat Posterior Capsule Neovascularization
We report a 64-year-old diabetic woman who developed neovascularization of the posterior capsule 2 years after cataract surgery and intraocular lens implantation. The patient was treated with single injection of 1.25 mg of intravitreal bevacizumab (Avastin) via pars plana. After one week, complete regression of the posterior capsule neovascularization was achieved allowing us to perform Nd: YAG...
متن کامل[Intravitreal injection of bevacizumab (Avastin) for retinal angiomatous proliferation].
CLINICAL CASE An 81-year-old man presented with stage 2 retinal angiomatous proliferation (RAP) as identified by fluorescein angiography and optical coherence tomography (OCT), and was shown to have a visual acuity (VA) of 20/40. One week after an intravitreal injection of bevacizumab (1.25 mg) the VA improved to 20/25, and the OCT showed a reduction of both intraretinal edema and pigment epith...
متن کاملElectrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).
PURPOSE Intravitreal bevacizumab (Avastin; Genentech Inc., San Francisco, CA) is a new treatment for age-related macular degeneration. The aim of this study was to evaluate retinal penetration and toxicity of bevacizumab. METHODS Ten albino rabbits were injected intravitreally with 0.1 mL (2.5 mg) of Avastin into one eye and 0.1 mL saline into the fellow eye. The electroretinogram (ERG) was r...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
journal of current ophthalmologyجلد ۲۱، شماره ۲، صفحات ۱۳-۱۸
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023